Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health

June 11, 2025 8:30 AM

Aspira Women's Health Inc., ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet needs in women's health.Aspira was originally awarded a $10 Million award...

Read more

Vitro Biopharma's AlloRx Stem Cell Therapy - Featured in New York Times Article on Health Secretary Kennedy's, Vision for Expanding Access to Regenerative Medicine

June 11, 2025 8:00 AM

Vitro Biopharma Inc. today announced that its AlloRx stem cell therapy was prominently featured in a New York Times article discussing the future of experimental therapies in the United States. The article, published June 5, 2025, examines Health Secretary Robert F. Kennedy Jr.'s recent policy statements on expanding patient access to regenerative medicine and explores the evolving regulatory landscape for treatments like stem cell therapies."We...

Read more

Moolec Science Regains NASDAQ Compliance

June 11, 2025 7:00 AM

Moolec Science SA (NASDAQ:MLEC) "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq Hearings Panel's ("Panel") decision dated April 3, 2025.On May 14, 2025, the Company effected a 1-for-10 reverse stock split, and the common shares have since...

Read more

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

June 11, 2025 4:10 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base.The agreement covers testing of...

Read more

Notice of Extra General Meeting in Biovica International AB

June 11, 2025 2:30 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Monday 14 July 2025, at 10:00 CET at Baker McKenzie Advokatbyrå on Vasagatan 7, 101 23 Stockholm.Right to attend and notificationShareholders who wish to attend the extra general meeting must:i. on the record date, which is Friday 4 July...

Read more

BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors

June 11, 2025 2:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated, positive Phase 1 data of intravenous (IV) and subcutaneous (SC) BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with...

Read more

Biovica Resolves on a Fully Guaranteed Rights Issue of Approximately SEK 80 million at SEK 0.63 Per Share

June 11, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - INSIDER INFORMATION: The Board of Directors of Biovica International AB (publ) ("Biovica" or the "Company") has today, subject to subsequent approval by an extraordinary general meeting, resolved to carry out a new issue of A-shares and B-shares of approximately SEK 80.1 million with preferential rights for the Company's shareholders (the "Rights Issue") and a directed issue of...

Read more

Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

June 10, 2025 12:40 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company's recent commercial momentum and its long-term commitment to transparency and value creation for patients, healthcare providers, and shareholders.The recently communicated partner agreement with Tempus AI in the U.S. and the agreement...

Read more

Vitro Biopharma's AlloRx Stem Cell Therapy Featured in New York Times Article on Health Secretary Kennedy's Vision for Expanding Access to Regenerative Medicine

June 10, 2025 8:00 AM

Vitro Biopharma Inc. today announced that its AlloRx stem cell therapy was prominently featured in a New York Times article discussing the future of experimental therapies in the United States. The article, published June 5, 2025, examines Health Secretary Robert F. Kennedy Jr.'s recent policy statements on expanding patient access to regenerative medicine and explores the evolving regulatory landscape for treatments like stem cell therapies."We...

Read more

PulpFixin Wins Prestigious SLAS New Product of the Year Award at SLAS Europe for Its Compostable AutoRacks

June 10, 2025 8:00 AM

PulpFixin, a leader in sustainable product solutions for the scientific community, has received the New Product of the Year Award at this year's SLAS Europe 2025 Conference and Exhibition. Its breakthrough AutoRacks - the first fully compostable automation-compatible racks, are designed to replace single-use plastic in high-throughput laboratory workflows. Finalists were judged on their product's technical merit, proof of concept, market...

Read more

AbTherx and Wield Therapeutics Partner to Advance New Antibody Therapies

June 10, 2025 6:00 AM

AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced an antibody discovery partnership with Wield Therapeutics, Inc. The partnership will leverage AbTherx's innovative Atlas™ Full Human Diversity Transgenic Mouse technology to deliver antibodies against a target selected by Wield.AbTherx's antibody discovery platform is built on two decades of experience...

Read more

FG001 clinical data in High-Grade Glioma is now published in Neurosurgery

June 10, 2025 3:25 AM

FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to announce its compelling phase I clinical data with FG001 has been published in Neurosurgery. The data is the first-in-human result of its proprietary near-infrared (NIR) optical imaging agent, FG001, in patients with malignant glioma undergoing surgery.The article,...

Read more

Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value

June 10, 2025 2:30 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers.Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader...

Read more

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

June 9, 2025 9:00 AM

Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.About Barinthus BiotherapeuticsBarinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their...

Read more

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

June 6, 2025 8:05 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in...

Read more

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

June 5, 2025 11:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that its founding members Markku Jalkanen, a director of the Company, and his spouse Sirpa Jalkanen have on 3 June 2025 donated 500,000 ordinary shares in the Company to the Finnish Foundation that bears their name ("Sirpa ja Markku Jalkasen Säätiö sr", Business ID 1729345-2)...

Read more

Disrupting Laboratory Care Models: How Lee Tafoya is Reimagining Diagnostic Logistics to Revolutionize Rural Healthcare Access

June 4, 2025 2:30 PM

In a healthcare landscape increasingly defined by innovation and accessibility, few professionals stand at the nexus of clinical expertise and strategic vision quite like Lee A. Tafoya. As a Business Development Executive at Midwest Innovation Laboratory, Tafoya is spearheading a radical transformation in how diagnostic laboratory services are delivered; especially to rural and underserved communities that have long struggled with gaps in...

Read more

BioInvent Presents at PAGE 2025 a Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Drug Candidate BI-1910

June 4, 2025 2:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the presentation of a poster highlighting the model-informed early clinical development of the company's anti-TNFR2 program BI-1910 at the Population Approach Group in Europe (PAGE) 2025 meeting, being held in Thessaloniki,...

Read more

Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth

June 3, 2025 6:10 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF) ("Lobe" or the "Company"), a growth-stage biopharmaceutical company focused on advancing innovative treatments for rare disease, is pleased to announce the appointment of Mr. Yong Yao, MBA, CGMA, FCMA as Chief Financial Officer & Executive Vice President, effective June 1, 2025.Mr. Yao brings over 25 years of leadership experience spanning corporate finance, biomedical innovation, and business...

Read more

Biomarker Data from Alligator Bioscience’s OPTIMIZE-1 Trial Presented at ASCO 2025 Annual Meeting

June 3, 2025 3:00 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that biomarker data from its OPTIMIZE-1 clinical trial were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.OPTIMIZE-1 is a Phase 1b/2 trial evaluating mitazalimab in combination with mFOLFIRINOX in first-line metastatic pancreatic cancer (mPDAC). The study has demonstrated strong clinical outcomes to date, including a ~30% survival rate at 24 months...

Read more